Roche: immunotherapy Tecentriq fails bladder cancer study
(CercleFinance.com) - Cancer immunotherapy Tecentriq - a key asset of Swiss drugmaker Roche - has failed in a phase III study to treat people with muscle-invasive urothelial cancer.
The study evaluating Tecentriq as an adjuvant (after surgery) monotherapy treatment failed to meet its primary endpoint of disease-free survival, the company said on Friday.
"Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult," Roche noted in a statement.
Regarding Tecentriq, Roche has other ongoing Phase III studies in early and advanced bladder cancer, as well as a development programme for lung, skin, breast, gastrointestinal, and head and neck cancers.
Roche shares are currently down 0.2% in Zurich.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The study evaluating Tecentriq as an adjuvant (after surgery) monotherapy treatment failed to meet its primary endpoint of disease-free survival, the company said on Friday.
"Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult," Roche noted in a statement.
Regarding Tecentriq, Roche has other ongoing Phase III studies in early and advanced bladder cancer, as well as a development programme for lung, skin, breast, gastrointestinal, and head and neck cancers.
Roche shares are currently down 0.2% in Zurich.
Copyright (c) 2020 CercleFinance.com. All rights reserved.